•
Mar 31, 2022

OrthoPediatrics Q1 2022 Earnings Report

OrthoPediatrics reported a revenue increase of 9% year-over-year, driven by growth in trauma and deformity, and scoliosis segments. The company increased its full-year revenue guidance for 2022.

Key Takeaways

OrthoPediatrics Corp. reported a 9% increase in revenue for Q1 2022, reaching $23.4 million compared to $21.5 million in Q1 2021. The company's U.S. revenue increased by 8%, while international revenue grew by 13%. Trauma and Deformity revenue increased by 13%, Scoliosis revenue increased by 1%, and Sports Medicine/Other revenue decreased by 4%. The company has increased its full year 2022 revenue guidance to $122 million to $125 million.

Total revenue reached $23.4 million, a 9% increase year-over-year.

U.S. revenue increased by 8%, while international revenue grew by 13%.

Trauma and Deformity revenue increased by 13%, Scoliosis revenue increased by 1%.

Full year 2022 revenue guidance increased to $122 million to $125 million.

Total Revenue
$23.4M
Previous year: $21.5M
+9.1%
EPS
-$0.3
Previous year: -$0.25
+20.0%
Gross Profit Margin
79.3%
Previous year: 76.1%
+4.2%
Gross Profit
$18.6M
Previous year: $16.3M
+13.7%
Cash and Equivalents
$18M
Previous year: $21.4M
-16.2%
Free Cash Flow
-$8.39M
Previous year: -$4.66M
+80.0%
Total Assets
$301M
Previous year: $313M
-3.9%

OrthoPediatrics

OrthoPediatrics

OrthoPediatrics Revenue by Segment

OrthoPediatrics Revenue by Geographic Location

Forward Guidance

For full year 2022, the Company now expects its full year revenue to be in the range of $122 million to $125 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income